Cardio-oncology & otherGuideline or statement
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)
- Scientific statement
Recommendations
As issued by the authors
US cost-effectiveness threshold defined as $120,000 per quality-adjusted life year gained
New level of certainty framework summarizing the strength of the available evidence
Guidance for identifying and synthesizing relevant high-quality evidence, developing economic value statements, and communicating level of certainty in such statements
Special considerations for CV drugs and devices; health equity considerations when interpreting cost-effectiveness analyses (CEAs); reference case defined for future CEAs
Original publication
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement). J Am Coll Cardiol. Published 25 September 2025. doi:10.1016/j.jacc.2025.05.009
Summarised from the published abstract; every number is checked against it